{"protocolSection": {"identificationModule": {"nctId": "NCT01058863", "orgStudyIdInfo": {"id": "ABS-AS-201"}, "organization": {"fullName": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}, "briefTitle": "A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma", "officialTitle": "A Double-blind, Randomized, Placebo-controlled, 5-way Crossover, Multicenter, Single-dose, Dose-ranging Study to Compare the Efficacy and Safety of Albuterol Spiromax\u00ae and ProAir\u00ae HFA in Adult and Adolescent Subjects Ages 12 and Older With Persistent Asthma"}, "statusModule": {"statusVerifiedDate": "2021-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-02"}, "primaryCompletionDateStruct": {"date": "2010-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-01-27", "studyFirstSubmitQcDate": "2010-01-28", "studyFirstPostDateStruct": {"date": "2010-01-29", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-05-19", "resultsFirstSubmitQcDate": "2015-05-19", "resultsFirstPostDateStruct": {"date": "2015-06-08", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2011-08-25", "dispFirstSubmitQcDate": "2011-08-25", "dispFirstPostDateStruct": {"date": "2011-08-29", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2021-11-05", "lastUpdatePostDateStruct": {"date": "2021-11-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study is examining how well a dry powder inhaler (DPI) of albuterol medication works to help adult and adolescent subjects 12 years of age and older with persistent asthma to improve lung function."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 72, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Albuterol Spiromax\u00ae 90 mcg", "type": "EXPERIMENTAL", "description": "A single dose of albuterol 90 mcg delivered with Spiromax\u00ae, an inhalation-driven, multi-dose dry powder inhaler. Placebo inhalers used to maintain the blind.", "interventionNames": ["Drug: Albuterol Spiromax\u00ae", "Other: Placebo Inhaler"]}, {"label": "Albuterol Spiromax\u00ae 180 mcg", "type": "EXPERIMENTAL", "description": "A single dose of albuterol 180 mcg delivered with Spiromax\u00ae, an inhalation-driven, multi-dose dry powder inhaler (2 inhalations). Placebo inhalers used to maintain the blind.", "interventionNames": ["Drug: Albuterol Spiromax\u00ae", "Other: Placebo Inhaler"]}, {"label": "ProAir\u00ae HFA 90 mcg", "type": "ACTIVE_COMPARATOR", "description": "A single dose of albuterol 90 mcg delivered with ProAir\u00ae, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind.", "interventionNames": ["Drug: ProAir\u00ae HFA", "Other: Placebo Inhaler"]}, {"label": "ProAir\u00ae HFA 180 mcg", "type": "ACTIVE_COMPARATOR", "description": "A single dose of albuterol 180 mcg delivered with ProAir\u00ae, a 'press-and-breathe', metered-dose, aerosol inhaler (2 inhalations). Placebo inhalers used to maintain the blind.", "interventionNames": ["Drug: ProAir\u00ae HFA", "Other: Placebo Inhaler"]}, {"label": "Placebo Inhaler", "type": "PLACEBO_COMPARATOR", "description": "Placebo delivered with Spiromax\u00ae, an inhalation-driven, multi-dose dry powder inhaler, and with ProAir\u00ae, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind.", "interventionNames": ["Other: Placebo Inhaler"]}], "interventions": [{"type": "DRUG", "name": "Albuterol Spiromax\u00ae", "description": "Albuterol Spiromax\u00ae delivers 90 mcg albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.", "armGroupLabels": ["Albuterol Spiromax\u00ae 180 mcg", "Albuterol Spiromax\u00ae 90 mcg"], "otherNames": ["ProAir\u00ae RespiClick, Albuterol multi-dose dry powder inhaler (MDPI)"]}, {"type": "DRUG", "name": "ProAir\u00ae HFA", "description": "ProAir\u00ae HFA delivers 90 mcg of albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.", "armGroupLabels": ["ProAir\u00ae HFA 180 mcg", "ProAir\u00ae HFA 90 mcg"], "otherNames": ["albuterol HFA-MDI"]}, {"type": "OTHER", "name": "Placebo Inhaler", "description": "Placebo delivered in both the Spiromax\u00ae and HFA inhalers to maintain the blind and also to support the placebo treatment arm.", "armGroupLabels": ["Albuterol Spiromax\u00ae 180 mcg", "Albuterol Spiromax\u00ae 90 mcg", "Placebo Inhaler", "ProAir\u00ae HFA 180 mcg", "ProAir\u00ae HFA 90 mcg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6)", "description": "FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. The baseline for each study day was the average of the 2 pre-dose FEV1 measurements on that study day.\n\nThe first baseline spirometry was obtained between 6-11 AM. The highest FEV1 value from two acceptable values was captured for calculation of the efficacy endpoints. Assessments were obtained at approximately 0.5 hours and immediately before dosing, and 5 minutes, 0.25, 0.50, 0.75, 1, 2, 3, 4, 5 and 6 hours after completion of dosing.", "timeFrame": "Day 1 up to Day 30"}], "secondaryOutcomes": [{"measure": "Baseline-adjusted Percent-Predicted Forced Expiratory Volume in 1 Second (PPFEV1) Area Under the Curve (AUC 0-6)", "description": "Percent-predicted FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. Percent-predicted FEV1 is the expected FEV1 taking into account age, height, gender and race, as per the National Health and Nutrition Examination Survey III (NHANES III) reference values.\n\nThe first baseline spirometry was obtained between 6-11 AM. The highest FEV1 value from two acceptable values was captured for calculation of the efficacy endpoints. Assessments were obtained at approximately 0.5 hours and immediately before dosing, and 5 minutes, 0.25, 0.50, 0.75, 1, 2, 3, 4, 5 and 6 hours after completion of dosing.", "timeFrame": "Day 1 up to Day 30"}, {"measure": "Participants With Treatment-Emergent Adverse Events", "description": "Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.", "timeFrame": "Day 1 up to Day 37"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Must provide written informed consent,\n* Be between 12 years of age and older,\n* Male or Female, females of non-child bearing potential or using reliable contraception\n* Asthma for at least 6 months, FEV1 (forced expiratory volume in 1 second) between 50-80% of predicted value, and reversibility greater than or equal to 15% following 180 mcg albuterol\n* Stable low dose of Inhaled Corticosteroids\n* Non-smoker, 12 months smoking-free and \\<=10-pack years history\n* Otherwise healthy\n* Other criteria apply\n\nExclusion Criteria:\n\n* Pregnant\n* Allergic to albuterol or severe milk protein allergy\n* Must not be on another trial for 30days.\n* Other criteria apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Teva Study Leader", "affiliation": "Teva Branded Pharmaceutical Products R&D, Inc.", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Teva Clinical Study Site", "city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Teva Clinical Study Site", "city": "Rolling Hills Est.", "state": "California", "zip": "90274", "country": "United States"}, {"facility": "Teva Clinical Study Site", "city": "San Diego", "state": "California", "zip": "92123", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Teva Clinical Study Site", "city": "Colorado Springs", "state": "Colorado", "zip": "080907", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Teva Clinical Study Site", "city": "Margate", "state": "Florida", "zip": "33036", "country": "United States", "geoPoint": {"lat": 26.24453, "lon": -80.20644}}, {"facility": "Teva Clinical Study Site", "city": "Miami", "state": "Florida", "zip": "33173", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Teva Clinical Study Site", "city": "Saint Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Teva Clinical Study Site", "city": "Skillman", "state": "New Jersey", "zip": "08558", "country": "United States", "geoPoint": {"lat": 40.42011, "lon": -74.7146}}, {"facility": "Teva Clinical Study Site", "city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Teva Clinical Study Site", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Teva Clinical Study Site", "city": "Dayton", "state": "Ohio", "zip": "45406", "country": "United States", "geoPoint": {"lat": 39.75895, "lon": -84.19161}}, {"facility": "Teva Clinical Study Site", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Teva Clinical Study Site", "city": "Portland", "state": "Oregon", "zip": "97213", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 163 patients were screened and 72 patients were randomized. Most screening failures did not qualify for the study based on reversibility or spirometry criteria.", "groups": [{"id": "FG000", "title": "All Randomized Participants", "description": "Participants were randomized to one of ten treatment sequences, which indicated the order of the 5 single-dose treatments administered in this 5-way crossover study."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "72"}]}, {"type": "Safety and ITT Populations", "achievements": [{"groupId": "FG000", "comment": "One patient was randomized in error and never received the study drug.", "numSubjects": "71"}]}, {"type": "Treated With Albuterol Spiromax\u00ae 90 mcg", "achievements": [{"groupId": "FG000", "numSubjects": "68"}]}, {"type": "Treated With Albuterol Spiromax\u00ae 180 mcg", "achievements": [{"groupId": "FG000", "numSubjects": "68"}]}, {"type": "Treated With ProAir\u00ae HFA 90 mcg", "achievements": [{"groupId": "FG000", "numSubjects": "70"}]}, {"type": "Treated With ProAir\u00ae HFA 180 mcg", "achievements": [{"groupId": "FG000", "numSubjects": "68"}]}, {"type": "Treated With Placebo Inhaler", "achievements": [{"groupId": "FG000", "numSubjects": "69"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "68"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Sponsor requested withdrawal", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Randomized in error", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Randomized and treated", "groups": [{"id": "BG000", "title": "Randomized Treated Participants", "description": "Participants were randomized to one of ten treatment sequences, which indicated the order of the 5 single-dose treatments administered in this 5-way crossover study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "71"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "43.3", "spread": "14.78"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "12 to <18 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}]}]}, {"title": "18 to 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "64"}]}]}, {"title": ">65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "41"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "30"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "54"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Not Latino or Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "67"}]}]}, {"title": "Latino or Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "169.1", "spread": "9.49"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "89.6", "spread": "22.77"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6)", "description": "FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. The baseline for each study day was the average of the 2 pre-dose FEV1 measurements on that study day.\n\nThe first baseline spirometry was obtained between 6-11 AM. The highest FEV1 value from two acceptable values was captured for calculation of the efficacy endpoints. Assessments were obtained at approximately 0.5 hours and immediately before dosing, and 5 minutes, 0.25, 0.50, 0.75, 1, 2, 3, 4, 5 and 6 hours after completion of dosing.", "populationDescription": "Intent to treat population: randomized participants who received at least 1 dose of randomized study medication and had at least 1 post-baseline assessment", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L*hour", "timeFrame": "Day 1 up to Day 30", "groups": [{"id": "OG000", "title": "Albuterol Spiromax\u00ae 90 mcg", "description": "A single dose of albuterol 90 mcg delivered with Spiromax\u00ae, an inhalation-driven, multi-dose dry powder inhaler. Placebo inhalers used to maintain the blind."}, {"id": "OG001", "title": "Albuterol Spiromax\u00ae 180 mcg", "description": "A single dose of albuterol 180 mcg delivered with Spiromax\u00ae, an inhalation-driven, multi-dose dry powder inhaler (2 inhalations). Placebo inhalers used to maintain the blind."}, {"id": "OG002", "title": "ProAir\u00ae HFA 90 mcg", "description": "A single dose of albuterol 90 mcg delivered with ProAir\u00ae, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind."}, {"id": "OG003", "title": "ProAir\u00ae HFA 180 mcg", "description": "A single dose of albuterol 180 mcg delivered with ProAir\u00ae, a 'press-and-breathe', metered-dose, aerosol inhaler (2 inhalations). Placebo inhalers used to maintain the blind."}, {"id": "OG004", "title": "Placebo Inhaler", "description": "Placebo delivered with Spiromax\u00ae, an inhalation-driven, multi-dose dry powder inhaler, and with ProAir\u00ae, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "70"}, {"groupId": "OG003", "value": "68"}, {"groupId": "OG004", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.21", "spread": "0.224"}, {"groupId": "OG001", "value": "1.39", "spread": "0.224"}, {"groupId": "OG002", "value": "1.12", "spread": "0.223"}, {"groupId": "OG003", "value": "1.33", "spread": "0.224"}, {"groupId": "OG004", "value": "0.24", "spread": "0.224"}]}]}], "analyses": [{"groupIds": ["OG001", "OG004"], "groupDescription": "Of interest was the mean difference between each active group and placebo at each dose level. Analyses were performed at the 2-sided 0.05 significance level in this sequence: Albuterol Spiromax 180 mcg versus placebo; Albuterol Spiromax 90 mcg versus placebo, ProAir HFA 180 mcg versus placebo, and ProAir HFA 90 mcg versus placebo. If a test was not significant, no further tests were done. This sequential procedure preserved the error rate for the family of tests at the 0.05 level.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "Significance at the 0.05 level.", "statisticalMethod": "ANOVA", "statisticalComment": "Fixed effects of baseline FEV1 as a covariate, sequence, treatment group, period, and center, and random effect for subject within sequence.", "paramType": "Mean Difference (Final Values)", "paramValue": "1.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.88", "ciUpperLimit": "1.42", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.136"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Of interest was the mean difference between each active group and placebo at each dose level. Analyses were performed at the 2-sided 0.05 significance level in this sequence: Albuterol Spiromax 180 mcg versus placebo; Albuterol Spiromax 90 mcg versus placebo, ProAir HFA 180 mcg versus placebo, and ProAir HFA 90 mcg versus placebo. If a test was not significant, no further tests were done. This sequential procedure preserved the error rate for the family of tests at the 0.05 level.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "Significance at the 0.05 level.", "statisticalMethod": "ANOVA", "statisticalComment": "Fixed effects of baseline FEV1 as a covariate, sequence, treatment group, period, and center, and random effect for subject within sequence.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.97", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.70", "ciUpperLimit": "1.24", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.136"}, {"groupIds": ["OG003", "OG004"], "groupDescription": "Of interest was the mean difference between each active group and placebo at each dose level. Analyses were performed at the 2-sided 0.05 significance level in this sequence: Albuterol Spiromax 180 mcg versus placebo; Albuterol Spiromax 90 mcg versus placebo, ProAir HFA 180 mcg versus placebo, and ProAir HFA 90 mcg versus placebo. If a test was not significant, no further tests were done. This sequential procedure preserved the error rate for the family of tests at the 0.05 level..", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "Significance at the 0.05 level.", "statisticalMethod": "ANOVA", "statisticalComment": "Fixed effects of baseline FEV1 as a covariate, sequence, treatment group, period, and center, and random effect for subject within sequence.", "paramType": "Mean Difference (Final Values)", "paramValue": "1.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.81", "ciUpperLimit": "1.35", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.136"}, {"groupIds": ["OG002", "OG004"], "groupDescription": "Of interest was the mean difference between each active group and placebo at each dose level. Analyses were performed at the 2-sided 0.05 significance level in this sequence: Albuterol Spiromax 180 mcg versus placebo; Albuterol Spiromax 90 mcg versus placebo, ProAir HFA 180 mcg versus placebo, and ProAir HFA 90 mcg versus placebo. If a test was not significant, no further tests were done. This sequential procedure preserved the error rate for the family of tests at the 0.05 level.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "Significance at the 0.05 level.", "statisticalMethod": "ANOVA", "statisticalComment": "Fixed effects of baseline FEV1 as a covariate, sequence, treatment group, period, and center, and random effect for subject within sequence.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.88", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.61", "ciUpperLimit": "1.15", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.136"}]}, {"type": "SECONDARY", "title": "Baseline-adjusted Percent-Predicted Forced Expiratory Volume in 1 Second (PPFEV1) Area Under the Curve (AUC 0-6)", "description": "Percent-predicted FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. Percent-predicted FEV1 is the expected FEV1 taking into account age, height, gender and race, as per the National Health and Nutrition Examination Survey III (NHANES III) reference values.\n\nThe first baseline spirometry was obtained between 6-11 AM. The highest FEV1 value from two acceptable values was captured for calculation of the efficacy endpoints. Assessments were obtained at approximately 0.5 hours and immediately before dosing, and 5 minutes, 0.25, 0.50, 0.75, 1, 2, 3, 4, 5 and 6 hours after completion of dosing.", "populationDescription": "Intent to treat population: randomized participants who received at least 1 dose of randomized study medication and had at least 1 post-baseline assessment", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "% predicted * hour", "timeFrame": "Day 1 up to Day 30", "groups": [{"id": "OG000", "title": "Albuterol Spiromax\u00ae 90 mcg", "description": "A single dose of albuterol 90 mcg delivered with Spiromax\u00ae, an inhalation-driven, multi-dose dry powder inhaler. Placebo inhalers used to maintain the blind."}, {"id": "OG001", "title": "Albuterol Spiromax\u00ae 180 mcg", "description": "A single dose of albuterol 180 mcg delivered with Spiromax\u00ae, an inhalation-driven, multi-dose dry powder inhaler (2 inhalations). Placebo inhalers used to maintain the blind."}, {"id": "OG002", "title": "ProAir\u00ae HFA 90 mcg", "description": "A single dose of albuterol 90 mcg delivered with ProAir\u00ae, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind."}, {"id": "OG003", "title": "ProAir\u00ae HFA 180 mcg", "description": "A single dose of albuterol 180 mcg delivered with ProAir\u00ae, a 'press-and-breathe', metered-dose, aerosol inhaler (2 inhalations). Placebo inhalers used to maintain the blind."}, {"id": "OG004", "title": "Placebo Inhaler", "description": "Placebo delivered with Spiromax\u00ae, an inhalation-driven, multi-dose dry powder inhaler, and with ProAir\u00ae, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "70"}, {"groupId": "OG003", "value": "68"}, {"groupId": "OG004", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "35.31", "spread": "4.497"}, {"groupId": "OG001", "value": "41.05", "spread": "4.495"}, {"groupId": "OG002", "value": "33.19", "spread": "4.461"}, {"groupId": "OG003", "value": "40.68", "spread": "4.496"}, {"groupId": "OG004", "value": "7.58", "spread": "4.482"}]}]}], "analyses": [{"groupIds": ["OG001", "OG004"], "groupDescription": "Of interest was the mean difference between each active group and placebo at each dose level. Analyses were performed at the 2-sided 0.05 significance level in this sequence: Albuterol Spiromax 180 mcg versus placebo; Albuterol Spiromax 90 mcg versus placebo, ProAir HFA 180 mcg versus placebo, and ProAir HFA 90 mcg versus placebo. If a test was not significant, no further tests were done. This sequential procedure preserved the error rate for the family of tests at the 0.05 level.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "Significance at the 0.05 level.", "statisticalMethod": "ANOVA", "statisticalComment": "Fixed effects of baseline PPFEV1 as a covariate, sequence, treatment group, period, and center, and random effect for subject within sequence.", "paramType": "Mean Difference (Final Values)", "paramValue": "33.47", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "26.21", "ciUpperLimit": "40.74", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.690"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Of interest was the mean difference between each active group and placebo at each dose level. Analyses were performed at the 2-sided 0.05 significance level in this sequence: Albuterol Spiromax 180 mcg versus placebo; Albuterol Spiromax 90 mcg versus placebo, ProAir HFA 180 mcg versus placebo, and ProAir HFA 90 mcg versus placebo. If a test was not significant, no further tests were done. This sequential procedure preserved the error rate for the family of tests at the 0.05 level.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "Significance at the 0.05 level.", "statisticalMethod": "ANOVA", "statisticalComment": "Fixed effects of baseline PPFEV1 as a covariate, sequence, treatment group, period, and center, and random effect for subject within sequence.", "paramType": "Mean Difference (Final Values)", "paramValue": "27.73", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "20.47", "ciUpperLimit": "34.99", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.686"}, {"groupIds": ["OG003", "OG004"], "groupDescription": "Of interest was the mean difference between each active group and placebo at each dose level. Analyses were performed at the 2-sided 0.05 significance level in this sequence: Albuterol Spiromax 180 mcg versus placebo; Albuterol Spiromax 90 mcg versus placebo, ProAir HFA 180 mcg versus placebo, and ProAir HFA 90 mcg versus placebo. If a test was not significant, no further tests were done. This sequential procedure preserved the error rate for the family of tests at the 0.05 level.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "Significance at the 0.05 level.", "statisticalMethod": "ANOVA", "statisticalComment": "Fixed effects of baseline PPFEV1 as a covariate, sequence, treatment group, period, and center, and random effect for subject within sequence.", "paramType": "Mean Difference (Final Values)", "paramValue": "33.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "25.84", "ciUpperLimit": "40.35", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.686"}, {"groupIds": ["OG002", "OG004"], "groupDescription": "Of interest was the mean difference between each active group and placebo at each dose level. Analyses were performed at the 2-sided 0.05 significance level in this sequence: Albuterol Spiromax 180 mcg versus placebo; Albuterol Spiromax 90 mcg versus placebo, ProAir HFA 180 mcg versus placebo, and ProAir HFA 90 mcg versus placebo. If a test was not significant, no further tests were done. This sequential procedure preserved the error rate for the family of tests at the 0.05 level.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.0001", "pValueComment": "Significance at the 0.05 level.", "statisticalMethod": "ANOVA", "statisticalComment": "Fixed effects of baseline PPFEV1 as a covariate, sequence, treatment group, period, and center, and random effect for subject within sequence.", "paramType": "Mean Difference (Final Values)", "paramValue": "25.61", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "18.36", "ciUpperLimit": "32.85", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.680"}]}, {"type": "SECONDARY", "title": "Participants With Treatment-Emergent Adverse Events", "description": "Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.", "populationDescription": "Safety population of all randomized participants who received at least one dose of randomized study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Day 1 up to Day 37", "groups": [{"id": "OG000", "title": "All Randomized Participants", "description": "Participants were randomized to one of five treatment arms, which indicated the order of the 5 single-dose treatments administered in this 5-way crossover study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}]}], "classes": [{"title": "Any adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}]}]}, {"title": "Treatment-related AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Withdrawn from study due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Any serious AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Treatment-related serious AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Onset treatment for AE: Placebo Inhaler", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Onset treatment for AE: Albuterol Spiromax 90mcg", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "Onset treatment for AE: Albuterol Spiromax 180mcg", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "Onset treatment for AE: ProAir HFA 90 mcg", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Onset treatment for AE: ProAir HFA 180 mcg", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Day 1 to Day 37", "eventGroups": [{"id": "EG000", "title": "Albuterol Spiromax\u00ae 90 mcg", "description": "A single dose of albuterol 90 mcg delivered with Spiromax\u00ae, an inhalation-driven, multi-dose dry powder inhaler. Placebo inhalers used to maintain the blind.", "seriousNumAffected": 0, "seriousNumAtRisk": 68, "otherNumAffected": 3, "otherNumAtRisk": 68}, {"id": "EG001", "title": "Albuterol Spiromax\u00ae 180 mcg", "description": "A single dose of albuterol 180 mcg delivered with Spiromax\u00ae, an inhalation-driven, multi-dose dry powder inhaler (2 inhalations). Placebo inhalers used to maintain the blind.", "seriousNumAffected": 0, "seriousNumAtRisk": 68, "otherNumAffected": 3, "otherNumAtRisk": 68}, {"id": "EG002", "title": "ProAir\u00ae HFA 90 mcg", "description": "A single dose of albuterol 90 mcg delivered with ProAir\u00ae, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind.", "seriousNumAffected": 0, "seriousNumAtRisk": 70, "otherNumAffected": 0, "otherNumAtRisk": 70}, {"id": "EG003", "title": "ProAir\u00ae HFA 180 mcg", "description": "A single dose of albuterol 180 mcg delivered with ProAir\u00ae, a 'press-and-breathe', metered-dose, aerosol inhaler (2 inhalations). Placebo inhalers used to maintain the blind.", "seriousNumAffected": 0, "seriousNumAtRisk": 68, "otherNumAffected": 2, "otherNumAtRisk": 68}, {"id": "EG004", "title": "Placebo Inhaler", "description": "Placebo delivered with Spiromax\u00ae, an inhalation-driven, multi-dose dry powder inhaler, and with ProAir\u00ae, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind.", "seriousNumAffected": 0, "seriousNumAtRisk": 69, "otherNumAffected": 2, "otherNumAtRisk": 69}], "otherEvents": [{"term": "Cyst", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 68}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 69}]}, {"term": "Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 69}]}, {"term": "Food allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 68}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 69}]}, {"term": "Localized infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 68}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 69}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 68}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 69}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 69}]}, {"term": "Thermal burn", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 68}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 69}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 69}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 68}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 69}]}, {"term": "Dysphonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 68}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 69}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 68}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 69}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data."}, "pointOfContact": {"title": "Director, Clinical Research", "organization": "Teva Branded Pharmaceutical Products, R&D Inc.", "email": "ustevatrials@tevapharm.com", "phone": "215-591-3000"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000420", "term": "Albuterol"}, {"id": "D000017265", "term": "Procaterol"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000013566", "term": "Sympathomimetics"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "asFound": "Diameter", "relevance": "HIGH"}, {"id": "M19560", "name": "Procaterol", "asFound": "IFN-alfa-2", "relevance": "HIGH"}, {"id": "M4854", "name": "Benzocaine", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M16345", "name": "Sympathomimetics", "relevance": "LOW"}, {"id": "T433", "name": "Tannic Acid", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "Ot", "name": "Other Dietary Supplements"}]}}, "hasResults": true}